An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate.

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Drugs in Research & Development Pub Date : 2025-06-01 Epub Date: 2025-05-25 DOI:10.1007/s40268-025-00509-6

Derek E Murrell, Benjamin C Kennard, Maria E Bertoni, David B Cluck, Jonathan P Moorman, Stacy D Brown, Kesheng Wang, Michelle M Duffourc, Sam Harirforoosh

{"title":"An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate.","authors":"Derek E Murrell, Benjamin C Kennard, Maria E Bertoni, David B Cluck, Jonathan P Moorman, Stacy D Brown, Kesheng Wang, Michelle M Duffourc, Sam Harirforoosh","doi":"10.1007/s40268-025-00509-6","DOIUrl":null,"url":null,"abstract":"Background and objectives: The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy and tolerability among patients. This study sought to investigate the relationship, if any, of single nucleotide polymorphisms (SNPs) and selected clinical parameters.Methods: The study population, predominantly Caucasian males with a median age of 53.0 years [interquartile range 46.0-59.0], was assayed for genetic variations using an iPLEX ADME PGx Pro v1.0 Panel.Results: Although several SNP relationships were found with both forms of tenofovir, many of the reported SNPs were displayed only in the comprehensive regimen grouping, making it difficult to distinguish between the two prodrug forms.Conclusions: Being an exploratory study, the findings of this substudy serve as potential avenues for further research.","PeriodicalId":49258,"journal":{"name":"Drugs in Research & Development","volume":" ","pages":"153-160"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185805/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Research & Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40268-025-00509-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy and tolerability among patients. This study sought to investigate the relationship, if any, of single nucleotide polymorphisms (SNPs) and selected clinical parameters.

Methods: The study population, predominantly Caucasian males with a median age of 53.0 years [interquartile range 46.0-59.0], was assayed for genetic variations using an iPLEX ADME PGx Pro v1.0 Panel.

Results: Although several SNP relationships were found with both forms of tenofovir, many of the reported SNPs were displayed only in the comprehensive regimen grouping, making it difficult to distinguish between the two prodrug forms.

Conclusions: Being an exploratory study, the findings of this substudy serve as potential avenues for further research.

查看原文本刊更多论文

两种逆转录酶抑制剂富马酸替诺福韦阿拉那胺和富马酸替诺福韦二氧吡酯的探索性药理学初步研究。

背景和目的：核苷类逆转录酶抑制剂富马酸替诺福韦阿拉那胺和富马酸替诺福韦二氧吡酯常用于治疗人类免疫缺陷病毒。此外，每种形式的替诺福韦都需要实验室监测，以确定患者的疗效和耐受性。本研究试图调查的关系，如果有的话，单核苷酸多态性（snp）和选定的临床参数。方法：研究人群主要为高加索男性，中位年龄为53.0岁[四分位数范围为46.0-59.0]，使用iPLEX ADME PGx Pro v1.0 Panel检测遗传变异。结果：尽管两种形式的替诺福韦都发现了一些SNP关系，但许多报道的SNP仅在综合方案分组中显示，这使得难以区分两种前药形式。结论：本子研究为探索性研究，为进一步研究提供了可能的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Research & Development Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy. The Journal includes: Clinical research on new and established drugs; Preclinical research of direct relevance to clinical drug development; Short communications and case study reports that meet the above criteria will also be considered; Reviews may also be considered.